Tiny trial hopes blood filtering eases rare stiff person syndrome
NCT ID NCT06703333
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This early pilot study will test the safety of a procedure called extracorporeal photopheresis (ECP) in just 3 adults with stiff person syndrome. ECP involves filtering a person's blood, treating it with light and a drug, then returning it to the body. The goal is to see if patients can tolerate the 18 sessions over 6 months without serious side effects. This is a safety-only trial, not designed to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- extracorporeal photopheresis (ECP)
- What this could lead to
- If this treatment is safe, it could point toward a new way to manage stiff person syndrome symptoms.
- What could go wrong
- This is a very early, tiny pilot study with only 3 people. It is designed to test safety, not effectiveness, so it may not lead to any treatment change.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abu Dhabi Stem Cells Center
Abu Dhabi, 4600, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- New hope for stiff person syndrome: drug trial aims to ease muscle stiffness and improve walking
- Engineered immune cells take on lupus and scleroderma in early trial
- Could a stem cell transplant stop the immune system from attacking the brain?
- CAR T-Cell therapy: what happens years later?
- Experimental CAR-T therapy targets Hard-to-Treat brain autoimmune diseases